awmsg logo



ursodeoxycholic acid (Ursofalk®)


Reference No. 2610

Publication date:
03/05/2016


Appraisal information

ursodeoxycholic acid (Ursofalk®) 250 mg hard capsules
ursodeoxycholic acid (Ursofalk®) 500 mg film-coated tablet
ursodeoxycholic acid (Ursofalk®) 250 mg/5 ml oral suspension


Company: Dr Falk Pharma UK Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 16/03/2016
AWMSG meeting date: 20/04/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1016
Ministerial ratification: 29/04/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ursodeoxycholic acid (Ursofalk®) is recommended for use within NHS Wales for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download